Trials / Completed
CompletedNCT00780052
Infusional C-myb ASODN in Advanced Hematologic Malignancies
Infusional C-myb Antisense Oligodeoxynucleotide in Advanced Hematological Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether C-myb Antisense (AS) Oligonucleotides (ODNs)is a possible treatment modality for advanced hematologic malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | c-myb AS ODN | Subjects will be admitted to the hospital to receive c-myb AS ODN as a 24-hour continuous intravenous infusion over 7 days. Dose level is increased with each new subject to determine if there is a MTD. |
Timeline
- Start date
- 2002-09-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2008-10-27
- Last updated
- 2016-09-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00780052. Inclusion in this directory is not an endorsement.